Gainers

• DataMEDS AI (NASDAQ:MEDS) shares increased by 12.9% to $4.24 during Friday's after-market session. The market value of their outstanding shares is at $14.8 million.
• Geovax Labs (NASDAQ:GOVX) stock rose 9.27% to $0.39. The market value of their outstanding shares is at $1.9 million.
• Alaunos Therapeutics (NASDAQ:TCRT) stock moved upwards by 9.16% to $1.31. The market value of their outstanding shares is at $4.0 million.
• BGM Group (NASDAQ:BGM) stock rose 7.56% to $0.27. The market value of their outstanding shares is at $103.7 million.
• Apimeds Pharmaceuticals (AMEX:APUS) shares moved upwards by 6.77% to $1.89. The company's market cap stands at $2.5 million.
• Gossamer Bio (NASDAQ:GOSS) stock increased by 6.33% to $11.41. The company's market cap stands at $73.0 million.

Losers

• IM Cannabis (NASDAQ:IMCC) stock fell 11.3% to $3.75 during Friday's after-market session. The market value of their outstanding shares is at $1.0 million.
• Citius Oncology (NASDAQ:CTOR) shares declined by 8.78% to $1.04. The market value of their outstanding shares is at $107.8 million.
• Telomir Pharmaceuticals (NASDAQ:TELO) stock declined by 8.0% to $1.13. The market value of their outstanding shares is at $77.0 million.
• Pasithea Therapeutics (NASDAQ:KTTA) stock declined by 7.36% to $0.49. The company's market cap stands at $16.9 million.
• Mira Pharmaceuticals (NASDAQ:MIRA) shares decreased by 6.29% to $0.78. The company's market cap stands at $31.9 million.
• Pulsenmore (NASDAQ:PLSM) stock decreased by 6.25% to $2.25. The company's market cap stands at $15.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.